相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nanoparticle delivery systems to combat drug resistance in ovarian cancer
Emily M. Miller et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Ovarian Cancer, Version 2.2020
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Advances in epigenetic therapeutics with focus on solid tumors
Ning Jin et al.
CLINICAL EPIGENETICS (2021)
Tumor hypoxia: The major culprit behind cisplatin resistance in cancer patients
Nalini Devarajan et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study
Rebecca Kristeleit et al.
GYNECOLOGIC ONCOLOGY (2021)
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
Kristie-Ann Dickson et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
Chunfeng Xie et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Extracellular vesicles as a next-generation drug delivery platform
Inge Katrin Herrmann et al.
NATURE NANOTECHNOLOGY (2021)
Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells
Jerneja Kladnik et al.
CANCERS (2021)
Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer
Amal A. Al-Dossary et al.
CANCERS (2021)
Novel organo-osmium(ii) proteosynthesis inhibitors active against human ovarian cancer cells reduce gonad tumor growth in Caenorhabditis elegans
Enrique Ortega et al.
INORGANIC CHEMISTRY FRONTIERS (2021)
Structural basis of homologous recombination
Yueru Sun et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Ligand-Controlled Reactivity and Cytotoxicity of Cyclometalated Rhodium(III) Complexes
Wen-Ying Zhang et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2020)
Thiourea and Guanidine Compounds and Their Iridium Complexes in Drug-Resistant Cancer Cell Lines: Structure-Activity Relationships and Direct Luminescent Imaging
Samuel J. Thomas et al.
CHEMMEDCHEM (2020)
Palladium(II)-η3-Allyl Complexes BearingN-TrifluoromethylN-Heterocyclic Carbenes: A New Generation of Anticancer Agents that Restrain the Growth of High-Grade Serous Ovarian Cancer Tumoroids
Thomas Scattolin et al.
CHEMISTRY-A EUROPEAN JOURNAL (2020)
In vitro and in vivo anticancer activity of tridentate thiosemicarbazone copper complexes: Unravelling an unexplored pharmacological target
Mauro Carcelli et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
L. R. Duska et al.
GYNECOLOGIC ONCOLOGY (2020)
The development of a homologous recombination deficiency (HRD) score to identify HR-deficient tumors.
Xiaohua Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer
Qingfei Zhang et al.
NANO LETTERS (2020)
The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells
Xiaohui Zhang et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2020)
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia et al.
CANCER TREATMENT REVIEWS (2020)
Extracellular Vesicles in Cancer Metastasis: Potential as Therapeutic Targets and Materials
Akiko Kogure et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma
Ke Gong et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2020)
Epigenetics and epigenomics: underlying mechanisms, relevance, and implications in crop improvement
Gaurav Agarwal et al.
FUNCTIONAL & INTEGRATIVE GENOMICS (2020)
Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer
L. Loverix et al.
GYNECOLOGIC ONCOLOGY (2020)
A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest
Michael Tsabar et al.
CELL REPORTS (2020)
Facile synthesis of heterobimetallic [Fe II (?-diphosphine)Ru II ] and homobimetallic [Fe II (?-diphosphine)Fe II ] complexes and their in vitro cytotoxic activity on cisplatin-resistant cancer cells
Danya BenYosef et al.
INORGANICA CHIMICA ACTA (2020)
Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models
Safiah Ibrahim Althurwi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
High Expression of Nuclear Transcription Factor-κB is Associated with Cisplatin Resistance and for Ovarian Cancer
Yanyan Kan et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Role of Nucleotide Excision Repair in Cisplatin Resistance
Mingrui Duan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Qiao Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer
Dansaem Lim et al.
BMB REPORTS (2020)
Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine
M. Parhizkar et al.
NANOSCALE ADVANCES (2020)
Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein
Brian Kawahara et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2019)
pH-Responsive Polymer Nanoparticles for Drug Delivery
Nayeleh Deirram et al.
MACROMOLECULAR RAPID COMMUNICATIONS (2019)
Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines using Approved Drugs and Bioactive Compounds
Kirill Gorshkov et al.
TRANSLATIONAL ONCOLOGY (2019)
BCL-2 family isoforms in apoptosis and cancer
Chloe F. A. Warren et al.
CELL DEATH & DISEASE (2019)
Recent advances in polymer-based drug delivery systems for local anesthetics
Bo Wang et al.
ACTA BIOMATERIALIA (2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2019)
Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives
Muhammad Altaf et al.
CANCERS (2019)
Cisplatin: The first metal based anticancer drug
Sumit Ghosh
BIOORGANIC CHEMISTRY (2019)
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial
E. Pujade-Lauraine et al.
GYNECOLOGIC ONCOLOGY (2019)
A phase II trial of pembrolizumab in combinationwith bevacizumab and oral metronomic cyclophosphamide for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
E. Zsiros et al.
GYNECOLOGIC ONCOLOGY (2019)
β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer
Piera Tocci et al.
NATURE COMMUNICATIONS (2019)
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2019)
New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
Shang-Hung Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Shahin Aghamiri et al.
NANOMEDICINE (2019)
Ovarian damage from chemotherapy and current approaches to its protection
N. Spears et al.
HUMAN REPRODUCTION UPDATE (2019)
New findings on the antiproliferative activity of the silver(I) complex with 5-fluorouracil against human multi-resistant NCI/ADR-RES ovarian tumor cells
Julia H. Bormio Nunes et al.
TOXICOLOGY IN VITRO (2019)
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer A Phase 2 Clinical Trial
Joyce F. Liu et al.
JAMA ONCOLOGY (2019)
Core fucosylation of copper transporter 1 plays a crucial role in cisplatin-resistance of epithelial ovarian cancer by regulating drug uptake
Xiaoxue Lv et al.
MOLECULAR CARCINOGENESIS (2019)
Sensitization of cisplatin-resistant ovarian cancer cells by magnetite iron oxide nanoparticles: an in vitro study
Kurtulus Gokduman
NANOMEDICINE (2019)
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Giovanna Damia et al.
CANCERS (2019)
siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer
Christopher Halbur et al.
SLAS TECHNOLOGY (2019)
Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry
Xue Zhang et al.
JOURNAL OF CANCER (2019)
Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer
Lawrence B. Mensah et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2019)
Stimuli-Responsive Drug Release from Smart Polymers
Carlos M. Wells et al.
JOURNAL OF FUNCTIONAL BIOMATERIALS (2019)
Anticancer platinum-based complexes with non-classical structures
Linxiang Cai et al.
APPLIED ORGANOMETALLIC CHEMISTRY (2018)
MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B
Fang Xiao et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation
Si Sun et al.
CANCER SCIENCE (2018)
A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
Mingming Miao et al.
GYNECOLOGIC ONCOLOGY (2018)
Theaflavin-3,3-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells
Haibo Pan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Scutellaria baicalensis targets the hypoxia-inducible factor-1 and enhances cisplatin efficacy in ovarian cancer
Imran Hussain et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2018)
Molecular mechanisms of drug resistance in ovarian cancer
Leyla Norouzi-Barough et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
siRNA in ovarian cancer - Delivery strategies and targets for therapy
Dirk van den Brand et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
Sophia A. Shahin et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2018)
Exosome: Function and Role in Cancer Metastasis and Drug Resistance
Chengcheng Zhang et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2018)
FABP4 as a key determinant of metastatic potential of ovarian cancer
Kshipra M. Gharpure et al.
NATURE COMMUNICATIONS (2018)
PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer
Chitra Risnayanti et al.
SCIENTIFIC REPORTS (2018)
PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs
Tabassum Khan et al.
FRONTIERS IN PHARMACOLOGY (2018)
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
Chun-Yan Lan et al.
LANCET ONCOLOGY (2018)
PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection
Rachel M. McQuade et al.
PHARMACOLOGICAL RESEARCH (2018)
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Reema Narayan et al.
PHARMACEUTICS (2018)
944PQUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset
K N Moore et al.
ANNALS OF ONCOLOGY (2018)
Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
Xuejiao Li et al.
BIOINORGANIC CHEMISTRY AND APPLICATIONS (2018)
The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation
Hao Wang et al.
CELL DEATH & DISEASE (2018)
Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion
Haixia Wang et al.
JOURNAL OF OVARIAN RESEARCH (2018)
Immune Checkpoints as Therapeutic Targets in Autoimmunity
Christopher Paluch et al.
FRONTIERS IN IMMUNOLOGY (2018)
Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies
Federica Tomao et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Roberto Sorio et al.
GYNECOLOGIC ONCOLOGY (2017)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza et al.
GYNECOLOGIC ONCOLOGY (2017)
Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
Mohamed Wehbe et al.
INVESTIGATIONAL NEW DRUGS (2017)
Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
Seung Min Kim et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer
Yakup Bozkaya et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2017)
Liposome-based drug co-delivery systems in cancer cells
Sepideh Zununi Vahed et al.
MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS (2017)
Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models
Cai M. Roberts et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Saikosaponin-d, a calcium mobilizing agent, sensitizes chemoresistant ovarian cancer cells to cisplatin-induced apoptosis by facilitating mitochondrial fission and G2/M arrest
Hideaki Tsuyoshi et al.
ONCOTARGET (2017)
Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer
Jia Liu et al.
ONCOTARGET (2017)
Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer
Magdalena Ratajska et al.
ONCOTARGET (2017)
Exosomes as mediators of platinum resistance in ovarian cancer
Jennifer Crow et al.
ONCOTARGET (2017)
The use of natural compounds for the targeting and chemoprevention of ovarian cancer
Francesca Pistollato et al.
CANCER LETTERS (2017)
The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
Leli Zeng et al.
CHEMICAL SOCIETY REVIEWS (2017)
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer
Michael J. Pishvaian et al.
BRITISH JOURNAL OF CANCER (2017)
Current status and future directions of anti-angiogenic therapy for gliomas
Wolfgang Wick et al.
NEURO-ONCOLOGY (2016)
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
F. Trillsch et al.
ANNALS OF ONCOLOGY (2016)
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
Nazila Kamaly et al.
CHEMICAL REVIEWS (2016)
Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Zbynek Heger et al.
CURRENT DRUG TARGETS (2016)
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Jamie I. Fletcher et al.
DRUG RESISTANCE UPDATES (2016)
Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer
Jun Liang et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2016)
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
Susan M. Domchek et al.
GYNECOLOGIC ONCOLOGY (2016)
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
Bowen Du et al.
MOLECULES (2016)
Nanostructured lipid carriers: Promising drug delivery systems for future clinics
Ana Beloqui et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2016)
Cisplatin resistance and opportunities for precision medicine
Lauren Amable
PHARMACOLOGICAL RESEARCH (2016)
Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems
Jafar Ezzati Nazhad Dolatabadi et al.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY (2016)
The functions and clinical applications of tumor-derived exosomes
Yingkuan Shao et al.
ONCOTARGET (2016)
Self-assembled nanoscale coordination polymers carrying siRNAs and cisplatin for effective treatment of resistant ovarian cancer
Chunbai He et al.
BIOMATERIALS (2015)
The development of PARP inhibitors in ovarian cancer: from bench to bedside
Yvette Drew
BRITISH JOURNAL OF CANCER (2015)
Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway
Qiaoyun Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
The role of ABC transporters in ovarian cancer progression and chemoresistance
M. P. Ween et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity
M. L. Disis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy
Helen H. W. Chen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells
Ryan Charles Pink et al.
GYNECOLOGIC ONCOLOGY (2015)
Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy
Michal Pastorek et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway
Haizhi Huang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells
Yifei Wang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex
Jong-Hwan Lee et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2015)
Broad targeting of resistance to apoptosis in cancer
Ramzi M. Mohammad et al.
SEMINARS IN CANCER BIOLOGY (2015)
Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer
Andrew J. Wilson et al.
JOURNAL OF OVARIAN RESEARCH (2015)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Ovarian cancer stem cells: Are they real and why are they important?
Monjri M. Shah et al.
GYNECOLOGIC ONCOLOGY (2014)
The Diarylheptanoid Hirsutenone Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin via Modulation of Apoptosis-inducing Factor and X-linked Inhibitor of Apoptosis
Lee Farrand et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
Juan Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Emodin Augments Cisplatin Cytotoxicity in Platinum-Resistant Ovarian Cancer Cells via ROS-Dependent MRP1 Downregulation
Jun Ma et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo
Sutapa Sinha et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK
Quentin Q. Li et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Emma L. Barber et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2013)
Various modes of cell death induced by DNA damage
O. Surova et al.
ONCOGENE (2013)
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
Alexandria M. Haslehurst et al.
BMC CANCER (2012)
Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum
Julie A. DeLoia et al.
GYNECOLOGIC ONCOLOGY (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling
C. Zeller et al.
ONCOGENE (2012)
Subcellular targets of cisplatin cytotoxicity: An integrated view
Sandra M. Sancho-Martinez et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Delivery of chemotherapeutic drugs in tumour cell-derived microparticles
Ke Tang et al.
NATURE COMMUNICATIONS (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo
Yuxing Zhang et al.
CANCER LETTERS (2011)
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
Jalid Sehouli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial J. Wheate et al.
DALTON TRANSACTIONS (2010)
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander et al.
GYNECOLOGIC ONCOLOGY (2010)
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro
Michaela L. Krieger et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77 Å resolution
Ryan C. Todd et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2010)
Regulation of Copper Transporter 2 Expression by Copper and Cisplatin in Human Ovarian Carcinoma Cells
Brian G. Blair et al.
MOLECULAR PHARMACOLOGY (2010)
Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian Cells
Christopher Hom et al.
SMALL (2010)
Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth
Murali M. Yallapu et al.
JOURNAL OF OVARIAN RESEARCH (2010)
Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Rosaria Gangemi et al.
CURRENT MEDICINAL CHEMISTRY (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
Platinum resistance: The role of DNA repair pathways
Lainie P. Martin et al.
CLINICAL CANCER RESEARCH (2008)
Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-kappaB
Leigh A Solomon et al.
Journal of Ovarian Research (2008)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The resurgence of platinum-based cancer chemotherapy
Lloyd Kelland
NATURE REVIEWS CANCER (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer
Tamar Safra et al.
GYNECOLOGIC ONCOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells
Sooyong Lee et al.
GYNECOLOGIC ONCOLOGY (2007)
Enhanced γ-glutamylcysteine synthetase activity decreases drug-induced oxidative stress levels and cytotoxicity
Gokul C. Das et al.
MOLECULAR CARCINOGENESIS (2006)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance
Xinjian Lin et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Targeting XIAP for the treatment of malignancy
AD Schimmer et al.
CELL DEATH AND DIFFERENTIATION (2006)
A plausible model for the digital response of p53 to DNA damage
L Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients
P Surowiak et al.
VIRCHOWS ARCHIV (2005)
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
A Berkenblit et al.
GYNECOLOGIC ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells
A Mansouri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines
Y Najajreh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum
P Rosenberg et al.
ACTA ONCOLOGICA (2002)
Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells
T Minko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors
T Satoh et al.
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2001)
Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: Improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA
MS Davies et al.
INORGANIC CHEMISTRY (2000)
分享论文
